Basis for Success of Multidrug-Resistant Enterobacteriaceae

多重耐药肠杆菌科细菌的成功基础

• 批准号: 9354929
• 负责人: Frank DeLeo
• 金额: $ 66.39万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9354929
• 关键词: Anabolism; Area; Country; Enterobacteriaceae; Evolution; Genes; Genetic Recombination; Human; Immune system; Infection; Klebsiella pneumonia bacterium; Multi-Drug Resistance; Polysaccharides; Research; Testing; United States; base; capsule; carbapenem resistance; design; killings; neutrophil; novel diagnostics; prevent; success; therapeutic vaccine; trait

It remains unclear why the ST258 lineage is the most prevalent cause of multidrug resistant K. pneumoniae infections in the United States and other countries. To that end, we continued our research directed to better understand of the basis for the success of ST258. These studies included further analysis of region of recombination that encompasses the genes encoding capsule polysaccharide biosynthesis machinery. In addition, we studied the interaction of carbapenem-resistant Klebsiella pneumoniae (ST258) with human neutrophils to test the hypothesis that this strain has enhanced capacity to circumvent killing by the innate immune system. Our findings will accelerate research on novel diagnostic, therapeutic, and vaccine strategies designed to prevent and/or treat infections caused by multidrug resistant K. pneumoniae.

目前尚不清楚为什么ST 258谱系是多药耐药克雷伯菌最常见的原因。肺炎感染在美国和其他国家。为此，我们继续进行研究，以更好地了解ST 258成功的基础。这些研究包括对重组区域的进一步分析，所述重组区域包括编码荚膜多糖生物合成机制的基因。 此外，我们研究了碳青霉烯类耐药肺炎克雷伯菌（ST 258）与人中性粒细胞的相互作用，以检验该菌株具有增强的能力来规避先天免疫系统的杀伤的假设。 我们的研究结果将加速新的诊断，治疗和疫苗策略的研究，旨在预防和/或治疗由多药耐药K。肺炎。